Trial Profile
Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms TREAT
- Sponsors Takeda
- 01 Feb 2017 Results published in the American Journal of Respiratory and Critical Care Medicine
- 18 May 2016 Primary endpoint has not been met. (Change in sputum neutrophil counts [cells/g sputum] from Day 1 to Day 14 post exacerbation), as per results presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society.